Advanced Search

Show simple item record

dc.contributor.authorErtas, Merve
dc.contributor.authorSahin, Zafer
dc.contributor.authorBulbul, Emre F.
dc.contributor.authorBender, Ceysu
dc.contributor.authorBiltekin, Sevde N.
dc.contributor.authorBerk, Barkin
dc.contributor.authorDemirayak, Seref
dc.date.accessioned2020-07-09T20:58:59Z
dc.date.available2020-07-09T20:58:59Z
dc.date.issued2019
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.urihttps://doi.org/10.1002/ardp.201900033
dc.identifier.urihttps://hdl.handle.net/11421/24124
dc.descriptionSAHIN, ZAFER/0000-0002-5976-676X; Berk, Barkin/0000-0001-6047-2796en_US
dc.descriptionWOS: 000484830900001en_US
dc.descriptionPubMed: 31475759en_US
dc.description.abstractThe antioxidant, antimalarial, antibacterial, and antitumor activities of thiosemicarbazones have made this class of compounds important for medicinal chemists. in addition, thiosemicarbazones are among the most potent and well-known ribonucleotide reductase inhibitors. in this study, 24 new thiosemicarbazone derivatives were synthesized, and the structures and purity of the compounds were determined by IR, H-1 NMR, C-13 NMR, mass spectroscopy, and elemental analysis. the IC50 values of these 24 compounds were determined with an assay for ribonucleotide reductase inhibition. Compounds 19, 20, and 24 inhibited ribonucleotide reductase enzyme activity at a higher level than metisazone as standard. the cytotoxic effects of these compounds were measured on the MCF7 (human breast adenocarcinoma) and HEK293 (human embryonic kidney) cell lines. Similarly, compounds 19, 20, and 24 had a selective effect on the MCF7 and HEK293 cell lines, killing more cancer cells than cisplatin as standard. the compounds (especially 19, 20, and 24 as the most active ones) were then subjected to docking experiments to identify the probable interactions between the ligands and the enzyme active site. the complex formation was shown qualitatively. the ADME (absorption, distribution, metabolism, and excretion) properties of the compounds were analyzed using in-silico techniques.en_US
dc.description.sponsorshipAnadolu University Scientific Research Projects CommissionAnadolu University [1609S624]en_US
dc.description.sponsorshipAnadolu University Scientific Research Projects Commission, Grant/Award Number: 1609S624en_US
dc.language.isoengen_US
dc.publisherWiley-V C H Verlag Gmbhen_US
dc.relation.isversionof10.1002/ardp.201900033en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantitumor agentsen_US
dc.subjectribonucleotide reductaseen_US
dc.subjectthiazoleen_US
dc.subjectthiosemicarbazoneen_US
dc.titlePotent ribonucleotide reductase inhibitors: Thiazole-containing thiosemicarbazone derivativesen_US
dc.typearticleen_US
dc.relation.journalArchiv Der Pharmazieen_US
dc.contributor.departmentAnadolu Üniversitesien_US
dc.identifier.volume352en_US
dc.identifier.issue11en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record